Know Cancer

forgot password

Effect of Body Mass on Acyclovir Pharmacokinetics

18 Years
Open (Enrolling)
Hematological Malignancy, Pharmacokinetics of Acyclovir

Thank you

Trial Information

Effect of Body Mass on Acyclovir Pharmacokinetics

Inclusion Criteria:

- Age ≥18 years of age

- Receiving intravenous acyclovir 5 mg/kg (total body weight [TBW] for normal weight
patients and ideal body weight [IBW] for obese patients) as part of their routine

- Admitted as an inpatient with an expected stay of at least 24 hours

- Weight > 190% of ideal body weight (IBW) for "obese" patients or weight 80-120% of
IBW for matched control patients.

Exclusion Criteria:

- Receipt of acyclovir or similar agents (valacyclovir, ganciclovir, valganciclovir,
famciclovir) in the prior 24 hours

- Serum creatinine > 1.5 mg/dL at time of drug administration

- Hypersensitivity to acyclovir

- Patients requiring ventilator support or vasopressors in the prior 24 hours

- Receipt of probenecid, mycophenolate, tenofovir, or zidovudine in the prior 7 days

- Pregnant or breast-feeding

- Significant anatomical deformities that influence body habitus (i.e. amputation)

- Prior inclusion in this study

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Systemic clearance of acyclovir in obese and non-obese patients

Outcome Time Frame:

12 hours after acyclovir dose

Safety Issue:


Principal Investigator

Aaron Cumpston, PharmD

Investigator Role:

Principal Investigator

Investigator Affiliation:

West Virginia University


United States: Institutional Review Board

Study ID:

WVU 031112



Start Date:

October 2012

Completion Date:

January 2014

Related Keywords:

  • Hematological Malignancy
  • Pharmacokinetics of Acyclovir
  • Acyclovir
  • Pharmacokinetics
  • Obese
  • Non-obese
  • Weight
  • Distribution
  • Clearance
  • Neoplasms
  • Hematologic Neoplasms



West Virginia University Hospitals Mary Babb Randolph Cancer CenterMorgantown, West Virginia  26506